ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
23M of 23M shares
Institutional holders
307
53 new, 24 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 47 sales
Net sold $15.04M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 2,899,843 | 12.80% | 13G (passive) amendment | Jun 30, 2026 |
| Millennium Group Management LLC | 1,116,660 | 5.20% | 13G (passive) | May 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANIP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,958,646 | 12.88% | $244.92M | +211,154 | 0.00% |
| Soleus Capital Management, L.P. | 867,760 | 3.78% | $71.83M | +47,517 | 2.48% |
| Vanguard Capital Management LLC | 838,224 | 3.65% | $69.39M | +15,160 | 0.00% |
| State Street Corp | 831,647 | 3.62% | $68.86M | +60,060 | 0.00% |
| Tang Capital Management LLC | 707,500 | 3.08% | $58.57M | – | 2.66% |
| Dimensional Fund Advisors LP | 623,463 | 2.71% | $51.61M | +92,273 | 0.01% |
| American Century Companies Inc | 574,474 | 2.50% | $47.55M | +382,898 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 562,016 | 2.45% | $46.52M | −2,344 | 0.02% |
| Global Alpha Capital Management Ltd. | 558,003 | 2.43% | $46.19M | +196,763 | 2.77% |
| Geode Capital Management, LLC | 536,407 | 2.34% | $44.41M | +47,206 | 0.00% |
| Millennium Management LLC | 507,207 | 2.21% | $41.99M | −84,806 | 0.02% |
| Nuveen, LLC | 415,024 | 1.81% | $34.36M | +12,667 | 0.01% |
| Vanguard Portfolio Management LLC | 407,281 | 1.77% | $33.71M | +31,316 | 0.00% |
| Ranger Investment Management, L.P. | 343,150 | 1.49% | $28.41M | −16,933 | 1.80% |
| Deutsche Bank AG\ | 323,443 | 1.41% | $26.77M | +3,768 | 0.01% |
| Invesco Ltd. | 309,233 | 1.35% | $25.60M | −15,116 | 0.00% |
| UBS Group AG | 297,539 | 1.30% | $24.63M | −200,163 | 0.00% |
| Kennedy Capital Management LLC | 295,938 | 1.29% | $24.50M | +1,942 | 0.43% |
| Ameriprise Financial Inc | 287,382 | 1.25% | $23.79M | +17,120 | 0.00% |
| Nomura Asset Management International Inc. | 287,206 | 1.25% | $23.78M | −357 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 307 | 23M | 100.0% | 53 / 120 | 89 / 24 | 3M | 3M |
| Q1 2026 | 281 | 23M | 100.0% | 45 / 111 | 83 / 45 | 6M | 3M |
| Q4 2025 | 285 | 21M | 92.2% | 49 / 113 | 79 / 31 | 4M | 3M |
| Q3 2025 | 269 | 21M | 89.5% | 62 / 82 | 85 / 24 | 5M | 4M |
| Q2 2025 | 232 | 20M | 86.9% | 28 / 88 | 77 / 25 | 3M | 3M |
| Q1 2025 | 230 | 20M | 87.2% | 48 / 63 | 75 / 20 | 3M | 2M |
| Q4 2024 | 205 | 19M | 84.1% | 31 / 69 | 60 / 31 | 3M | 3M |
| Q3 2024 | 208 | 19M | 84.8% | 39 / 87 | 43 / 30 | 8M | 2M |
| Q2 2024 | 201 | 15M | 66.7% | 33 / 73 | 63 / 30 | 2M | 2M |
| Q1 2024 | 200 | 15M | 64.6% | 41 / 65 | 53 / 22 | 2M | 1M |
| Q4 2023 | 182 | 14M | 61.3% | 31 / 55 | 53 / 34 | 2M | 2M |
| Q3 2023 | 186 | 13M | 57.5% | 30 / 73 | 51 / 16 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ANIP | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,098,907 | 4.78% | $90.97M | 0.08% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 609,433 | 2.65% | $50.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 527,401 | 2.30% | $43.66M | 0.05% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 344,335 | 1.50% | $27.03M | 0.10% | May 31, 2026 |
| Oberweis Micro-Cap Fund | 256,300 | 1.12% | $21.22M | 1.31% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 224,189 | 0.98% | $17.76M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 209,103 | 0.91% | $17.31M | 0.02% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 204,469 | 0.89% | $16.93M | 0.01% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 195,005 | 0.85% | $16.14M | 1.38% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 189,667 | 0.83% | $15.70M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 166,958 | 0.73% | $13.82M | 0.08% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 163,598 | 0.71% | $13.54M | 0.16% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 151,712 | 0.66% | $12.02M | 2.55% | Jul 31, 2026 |
| abrdn U.S. Small Cap Equity Fund | 133,500 | 0.58% | $10.58M | 2.69% | Jul 31, 2026 |
| Invesco S&P SmallCap Momentum ETF | 122,617 | 0.53% | $9.72M | 0.32% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nikhil Lalwani | PRESIDENT & CEO, Director | 339,089 | 1.48% | Sep 16, 2026 |
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | 537,976 | 2.34% | Mar 2, 2026 |
| Stephen P. Carey | SVP & CFO | 168,993 | 0.74% | Sep 30, 2026 |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 73,924 | 0.32% | Sep 14, 2026 |
| Ori Gutwerg | SVP, GENERICS | 75,534 | 0.33% | Aug 11, 2026 |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 38,271 | 0.17% | May 13, 2026 |
| Christopher Mutz | HEAD OF RARE DISEASE | 91,309 | 0.40% | Mar 13, 2026 |
| Krista Davis | SVP, CHIEF HR OFFICER | 51,946 | 0.23% | Mar 10, 2026 |
| Chad Gassert | SVP - CORP. DEV. & STRATEGY | 233,406 | 1.02% | Mar 2, 2026 |
| Jeanne Thoma | Director | 26,762 | 0.12% | Sep 14, 2026 |
| Henry O. Gosebruch | Director | 6,662 | 0.03% | Aug 27, 2026 |
| Matthew J. Leonard | Director | 11,221 | 0.05% | Jun 10, 2026 |
| Thomas Haughey | Director | 38,878 | 0.17% | Jun 10, 2026 |
| Antonio R. Pera | Director | 27,017 | 0.12% | Jun 10, 2026 |
| Renee P. Tannenbaum | Director | 29,514 | 0.13% | Jun 10, 2026 |
| Patrick D. Walsh | Director | 38,432 | 0.17% | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen P. Carey SVP & CFO | Sep 29, 2026 | Sale(10b5-1 plan) | −2,850 | $73.00 | $208.05K | 168,993 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −5,400 | $71.00 | $383.40K | 339,089 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Sep 14, 2026 | Sale(10b5-1 plan) | −500 | $70.79 | $35.40K | 73,924 |
| Jeanne Thoma Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,000 | $71.53 | $71.53K | 26,762 |
| Stephen P. Carey SVP & CFO | Aug 31, 2026 | Sale(10b5-1 plan) | −2,850 | $72.80 | $207.48K | 171,843 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Aug 25, 2026 | Sale(10b5-1 plan) | −5,400 | $74.30 | $401.22K | 344,489 |
| Henry O. Gosebruch Director | Aug 19, 2026 | Award | +6,662 | – | – | 6,662 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Aug 13, 2026 | Sale(10b5-1 plan) | −500 | $75.48 | $37.74K | 74,424 |
| Ori Gutwerg SVP, GENERICS | Aug 10, 2026 | Sale | −3,162 | $77.00 | $243.47K | 75,534 |
| Stephen P. Carey SVP & CFO | Jul 29, 2026 | Sale(10b5-1 plan) | −2,850 | $81.36 | $231.88K | 174,693 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jul 18, 2026 | Tax withholding | −2,466 | $79.20 | $195.31K | 74,924 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jul 13, 2026 | Sale(10b5-1 plan) | −500 | $81.84 | $40.92K | 77,390 |
| Stephen P. Carey SVP & CFO | Jul 2, 2026 | Sale(10b5-1 plan) | −3,313 | $86.00 | $284.92K | 177,543 |
| Stephen P. Carey SVP & CFO | Jul 2, 2026 | Option exercise | +3,313 | $49.51 | $164.03K | 180,856 |
| Stephen P. Carey SVP & CFO | Jun 29, 2026 | Sale(10b5-1 plan) | −2,850 | $84.12 | $239.74K | 177,543 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jun 12, 2026 | Sale(10b5-1 plan) | −500 | $82.03 | $41.02K | 77,890 |
| Thomas Haughey Director | Jun 8, 2026 | Sale(10b5-1 plan) | −2,000 | $80.88 | $161.76K | 38,878 |
| Stephen P. Carey SVP & CFO | Jun 5, 2026 | Option exercise | +3,312 | $49.51 | $163.98K | 183,705 |
| Stephen P. Carey SVP & CFO | Jun 5, 2026 | Sale(10b5-1 plan) | −3,312 | $80.00 | $264.96K | 180,393 |
| Antonio R. Pera Director | May 21, 2026 | Award | +4,357 | – | – | 27,017 |
| Thomas Haughey Director | May 21, 2026 | Award | +4,357 | – | – | 40,878 |
| Renee P. Tannenbaum Director | May 21, 2026 | Award | +4,357 | – | – | 29,514 |
| Matthew J. Leonard Director | May 21, 2026 | Award | +4,357 | – | – | 11,221 |
| Jeanne Thoma Director | May 21, 2026 | Award | +4,357 | – | – | 27,762 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | May 13, 2026 | Sale(10b5-1 plan) | −500 | $78.16 | $39.08K | 78,390 |
| Patrick D. Walsh Director | May 13, 2026 | Sale | −10,000 | $80.63 | $806.30K | 38,432 |
| Ori Gutwerg SVP, GENERICS | May 12, 2026 | Sale | −2,772 | $79.50 | $220.37K | 78,696 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | May 12, 2026 | Sale | −459 | $79.21 | $36.36K | 38,271 |
| Patrick D. Walsh Director | May 11, 2026 | Sale | −3,973 | $80.75 | $320.82K | 48,432 |
| Nikhil Lalwani PRESIDENT & CEO, Director | May 11, 2026 | Sale | −55,000 | $77.57 | $4.27M | 349,889 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Apr 13, 2026 | Sale(10b5-1 plan) | −500 | $77.95 | $38.98K | 78,890 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2026 | Sale(10b5-1 plan) | −500 | $72.62 | $36.31K | 79,390 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 13, 2026 | Sale(10b5-1 plan) | −3,162 | $71.64 | $226.53K | 91,309 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | Mar 11, 2026 | Sale | −4,772 | $74.91 | $357.47K | 38,730 |
| Krista Davis SVP, CHIEF HR OFFICER | Mar 9, 2026 | Sale(10b5-1 plan) | −5,087 | $74.13 | $377.10K | 51,946 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 9, 2026 | Sale(10b5-1 plan) | −3,602 | $74.18 | $267.20K | 94,471 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Mar 7, 2026 | Tax withholding | −17,060 | $74.04 | $1.26M | 404,889 |
| Ori Gutwerg SVP, GENERICS | Mar 7, 2026 | Tax withholding | −3,314 | $74.04 | $245.37K | 81,468 |
| Stephen P. Carey SVP & CFO | Mar 7, 2026 | Tax withholding | −5,150 | $74.04 | $381.31K | 180,393 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 7, 2026 | Tax withholding | −3,314 | $74.04 | $245.37K | 98,073 |
| Krista Davis SVP, CHIEF HR OFFICER | Mar 6, 2026 | Sale(10b5-1 plan) | −1,485 | $75.00 | $111.38K | 57,033 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 6, 2026 | Sale(10b5-1 plan) | −2,121 | $74.22 | $157.42K | 101,387 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Sale | −3,312 | $75.42 | $249.79K | 189,543 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Option exercise | +3,312 | $49.51 | $163.98K | 192,855 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Sale | −4,000 | $75.56 | $302.24K | 185,543 |
| Ori Gutwerg SVP, GENERICS | Mar 3, 2026 | Sale | −2,060 | $76.50 | $157.59K | 84,782 |
| Patrick D. Walsh Director | Mar 3, 2026 | Sale | −6,000 | $74.23 | $445.38K | 52,405 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 2, 2026 | Sale(10b5-1 plan) | −417 | $74.00 | $30.86K | 103,508 |
| Christopher Mutz HEAD OF RARE DISEASE | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 103,925 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Feb 28, 2026 | Tax withholding | −12,217 | $73.90 | $902.84K | 421,949 |
| Ori Gutwerg SVP, GENERICS | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 86,842 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | Feb 28, 2026 | Tax withholding | −628 | $73.90 | $46.41K | 43,502 |
| Stephen P. Carey SVP & CFO | Feb 28, 2026 | Tax withholding | −2,773 | $73.90 | $204.92K | 189,543 |
| Krista Davis SVP, CHIEF HR OFFICER | Feb 28, 2026 | Tax withholding | −1,555 | $73.90 | $114.91K | 58,518 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Feb 28, 2026 | Tax withholding | −1,555 | $73.90 | $114.91K | 79,890 |
| Chad Gassert SVP - CORP. DEV. & STRATEGY | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 74,916 |
| Christopher Mutz HEAD OF RARE DISEASE | Feb 26, 2026 | Award | +21,306 | $77.15 | $1.64M | 106,146 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Feb 26, 2026 | Award | +75,592 | $77.15 | $5.83M | 434,166 |
| Ori Gutwerg SVP, GENERICS | Feb 26, 2026 | Award | +12,969 | $77.15 | $1.00M | 89,063 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | Feb 26, 2026 | Award | +6,021 | $77.15 | $464.52K | 44,130 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lalwani Nikhil Director, Officer | Oct 15, 2026 | 5,400 | $378.86K | Oct 15, 2026 | Restricted Stock Awards |
| Lalwani Nikhil Director, Officer | Sep 15, 2026 | 5,400 | $380.16K | Sep 15, 2026 | Restricted Stock Awards |
| Thoma Jeanne Director | Sep 11, 2026 | 1,000 | $71.46K | Sep 11, 2026 | Restricted Stock Awards |
| Lalwani Nikhil Director, Officer | Aug 25, 2026 | 5,400 | $400.52K | Aug 25, 2026 | RSA |
| P. Carey Stephen Officer | Jul 29, 2026 | 6,163 | $499.45K | Jul 29, 2026 | Restricted Stock Awards |
| Walsh Patrick Director | Jul 7, 2026 | 4,336 | $373.72K | Jul 7, 2026 | Restricted Stock |
| Haughey Thomas Director | Jun 8, 2026 | 2,000 | $162.22K | Jun 8, 2026 | Restricted Stock Awards |
| P. Carey Stephen Officer | Jun 5, 2026 | 11,862 | $939.47K | Jun 5, 2026 | Exercise of Stock Options |
| Patrick D. Walsh Director | May 13, 2026 | 10,000 | $795.60K | May 13, 2026 | Open Market Purchase |
| Walsh Patrick Director | May 11, 2026 | 3,973 | $320.82K | May 11, 2026 | Restricted Stock |
| Lalwani Nikhil Officer, Director | May 11, 2026 | 55,000 | $4.27M | May 11, 2026 | Performance Shares |
| P. Carey Stephen Officer | Mar 5, 2026 | 7,312 | $552.02K | Mar 5, 2026 | Restricted Stock |
| Walsh Patrick Director | Mar 3, 2026 | 6,000 | $445.39K | Mar 3, 2026 | Restricted Stock |
| Plawner Tannenbaum 2024 Rv Trust Renate Director | Dec 9, 2025 | 1,800 | $146.07K | Dec 5, 2025 | Restricted stock vesting under a registered plan |
| Walsh Patrick Director | Nov 13, 2025 | 8,643 | $750.91K | Nov 13, 2025 | Restricted Stock |